The development of effective mucosal vaccines has been hindered by the lack of useful adjuvants and our limited knowledge of their modes of action. Cholera toxin (CT) from Vibrio cholerae and Escherichia coli heat-labile enterotoxin (LT) are potent immunological adjuvants, as indicated by mouse vaccine studies, although their mechanisms of action are not fully understood. These toxins are holotoxins composed of an enzymatically active A subunit that is noncovalently linked to a pentamer of B subunits binding a variety of galactose-containing molecules present in the plasma membranes of eukaryotic cells. CT binds mostly to the ganglioside GM1, which is believed to be the major toxin receptor, whereas LT binds not only to GM1 but also to other glycosphingolipids. Once internalized, the A subunit ADP ribosylates the ␣ subunit of the GTP-binding regulatory protein Gs, thereby inducing permanent adenylate cyclase activation, resulting in an increase in the level of intracellular cyclic AMP (cAMP) (reviewed in reference 34).
The development of effective mucosal vaccines has been hindered by the lack of useful adjuvants and our limited knowledge of their modes of action. Cholera toxin (CT) from Vibrio cholerae and Escherichia coli heat-labile enterotoxin (LT) are potent immunological adjuvants, as indicated by mouse vaccine studies, although their mechanisms of action are not fully understood. These toxins are holotoxins composed of an enzymatically active A subunit that is noncovalently linked to a pentamer of B subunits binding a variety of galactose-containing molecules present in the plasma membranes of eukaryotic cells. CT binds mostly to the ganglioside GM1, which is believed to be the major toxin receptor, whereas LT binds not only to GM1 but also to other glycosphingolipids. Once internalized, the A subunit ADP ribosylates the ␣ subunit of the GTP-binding regulatory protein Gs, thereby inducing permanent adenylate cyclase activation, resulting in an increase in the level of intracellular cyclic AMP (cAMP) (reviewed in reference 34) .
The potentiation of antigen-presenting cell (APC) function is a major aspect of adjuvant action, and it has been shown that CT and LT induce maturation of both murine dendritic cells (DC) (26, 36) and human DC (5, 14, 15) . Several studies demonstrated the ability of these toxins to promote B-cell isotype switch differentiation in mice (19, 27) and upregulation of activation markers in both murine and human B cells (2) (3) (4) . While these toxins are potent adjuvants, their toxicity makes them unsuitable for human use. For this reason, a number of investigators have tried to develop nontoxic derivatives of CT and LT that retain adjuvanticity either by removing the A domain or by rendering it enzymatically inactive by site-directed mutagenesis (34) . Although the current data suggest that the enzymatic activity of CT and LT holotoxins is responsible for the most potent adjuvant activity, a number of reports proposed that there are multiple immune modulating pathways that are triggered by CT and LT, including mechanisms independent of ADP ribosyltransferase activity (11, 13, 30, 33, 42) . Numerous studies have suggested that engagement of the ganglioside GM1, the major receptor for CT and LT, is required for the ability of these molecules to modulate immune responses (22, 31) . Recently, workers demonstrated that in the absence of the toxic A subunit, the B subunit of CT (CT-B) induces intracellular signaling associated with the in vitro activation of murine B cells and macrophages (37) .
The majority of these studies have been performed with murine cells and have confirmed the in vivo adjuvanticity of nontoxic compounds, such as CT-B and LTK63, a mutant of LT lacking the ADP ribosyltransferase enzymatic activity, when they were mucosally delivered into animals, even if the immune responses observed in the in vivo studies were usually weaker than those induced by the wild-type toxins (6, 11, 20, 36, 40, 41) . In order to develop a mucosal adjuvant for human vaccine, the mechanism(s) of action of potential nontoxic adjuvants should be investigated in vitro by using human APC. It has been shown that the B-cell antigen-presenting functions may be important for the induction of optimal vaccine-induced responses (10, 35) . Moreover, B cells are present in mucosaassociated lymphoid tissues (8) , and their function in these sites is related not only to immunoglobulin (Ig) production but also to their antigen-presenting properties (24) . To elucidate the mechanisms by which enterotoxins modulate antigen-presenting properties, we decided to carry out a comprehensive and comparative analysis of the effects of the toxins and their nontoxic derivatives on the APC function of human B cells. Here we present evidence that CT and LT, as well as forskolin (FSK) and cAMP analogues, but not CT-B and LTK63, increase the activation of human B cells and induce improvement in their APC capability, indicating that the presence of the enzymatic subunit is critical for their adjuvanticity.
MATERIALS AND METHODS
Recombinant enterotoxins. CT and CT-B were purchased from List Biological Laboratories (Campbell, CA); E. coli LT was purchased from Swiss Serum Vaccine Institute (Berne, Switzerland); LTK63 was provided by Novartis (Siena, Italy); and FSK, dibutyryl-cAMP (Db-cAMP), and 8-bromo-cAMP (8Br-cAMP) were purchased from Sigma Chemical Co. (St. Louis, MO). Endotoxin contamination in adjuvant preparations was evaluated by Limulus amoebocyte lysate analysis (Pyrochrome; Associates of Cape Cod, Falmouth, MA). The concentration of endotoxin was less than 0.09 endotoxin unit /g in all of the preparations utilized in this study.
Isolation and activation of B cells. Human B cells were isolated from peripheral blood mononuclear cells (PBMC) from healthy donors by positive selection using anti-CD19 microbeads and the manufacturer's suggested protocol (Miltenyi Biotec S.r.l., Bologna, Italy). The cells obtained were Ͼ95% CD19 positive, as assessed by flow cytometry analysis. B cells were cultured in 24-well plates or in 96-well plates at a concentration of 1.5 ϫ 10 6 to 2 ϫ 10 6 cells/ml in RPMI 1640 medium (GIBCO Invitrogen, Paisley, United Kingdom) supplemented with 100 U/ml of penicillin-streptomycin-glutamine (GIBCO Invitrogen, Paisley, United Kingdom), 10% heat-inactivated fetal bovine serum (Euroclone, Life Sciences Division, Pero, Italy), sodium pyruvate (Euroclone), and nonessential amino acids (Euroclone). In order to obtain polyclonal stimulation, B cells were cultured in the presence of 2.5 g/ml of CpG ODN 2006 (MWG Biotech, MMedical, Milan, Italy), 50 U/ml of interleukin-2 (IL-2) (BD Biosciences, San Diego, CA), and 2 g/ml of anti-Ig monoclonal antibody (MAb) (Jackson ImmunoResearch Laboratories, Suffolk, United Kingdom). In addition, together with the stimuli, on day zero B cells were either treated with 3 g/ml of CT, 10 g/ml of CT-B, 0.1 g/ml of LT, 10 g/ml of LTK63, 50 M of FSK, 0.5 mM Db-cAMP, or 8Br-cAMP or left untreated. In some experiments CD27 ϩ and CD27 Ϫ B cells were isolated by sorting total B cells with FACSAria (BD Biosciences, San Diego, CA). Briefly, B cells were isolated by using anti-CD19 microbeads, as described above. CD27 ϩ and CD27 Ϫ B-cell subsets were purified based on CD27 cell surface expression by FACSAria after staining with phycoerythrin-conjugated anti-CD27 MAb (Immunological Sciences, Rome, Italy). Dead cells were excluded on the basis of propidium iodide (PI) (5 g/ml; BD Biosciences) fluorescence intensity. The two subpopulations were stimulated with polyclonal stimuli and treated with adjuvants as described above for the unfractionated B cells.
Determination of intracellular cAMP content. B cells (2 ϫ 10 5 cells in 200 l, seeded in duplicate) were stimulated and treated for 24 h with adjuvants or FSK or left untreated in the presence of 100 M 3-isobutyl-1-methylxanthine (Sigma Chemical Co., St. Louis, MO), which inhibits cAMP-hydrolyzing phosphodiesterases, in order to avoid cAMP degradation. The culture medium was removed after 10 min of centrifugation at 1,300 rpm, and cold 0.1 N HCl was used to lyse the cells. The intracellular cAMP content was measured by an enzyme-linked immunoassay by following the manufacturer's instructions (Biotrak EIA, GE Healthcare).
Flow cytometric immunofluorescence analysis of surface markers and apoptotic cells. B cells were stained with the following mouse anti-human MAbs obtained from Becton Dickinson (BD Biosciences, San Diego, CA): phycoerythrin-labeled anti-CD86, anti-HLA class I, anti-CD80, and anti-CD40 and peridinin chlorophyll protein-labeled anti-CD20 and anti-HLA class II. Isotypematched mouse IgG MAbs were used as controls. To evaluate B-cell death, stimulated B cells, treated as indicated above for 3 and 5 days, were stained with Annexin V-fluorescein isothiocyanate (FITC) plus PI (Annexin V-FITC apoptosis detection kit II; BD PharMingen, San Diego, CA) by following the manufacturer's instructions. Flow cytometric analysis of the cells was performed using a FACSCalibur and CellQuest software (BD Biosciences).
B-cell proliferation assay. PBMC or purified B cells were labeled with 2.5 M carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) in phosphate-buffered saline containing 1% fetal bovine serum for 10 min at 37°C, washed in complete RPMI 1640 medium, and then seeded in 24-well or 96-well culture plates (1.5 ϫ 10 6 cells/ml) containing polyclonal stimuli (see above) and subjected to different treatments. After 3 and 5 days of culture, the cells were washed and stained with MAbs against human CD4, CD8, or CD20 from Becton Dickinson. The amounts of cell proliferation in the cell populations were quantified by monitoring the sequential loss of fluorescence intensity of the CFSE-labeled cells using a FACSCalibur.
Mixed allogeneic cultures and antigen-specific presentation assay. Purified, stimulated B cells treated as indicated above or left untreated for 3 days, carefully washed, and irradiated (3,000 rads) were cocultured with allogeneic PBMC labeled with CFSE (see above). A total of 1 ϫ 10 5 PBMC per well were seeded onto 96-well plates (Sigma-Aldrich S.r.l., Milan, Italy) with titrated numbers of irradiated B cells (the B cell/PBMC ratio ranged from 1:16 to 1:1). After 3 days of coculture, cells were collected and stained with anti-human CD4 or antihuman CD8 MAbs. The levels of PBMC, CD4
ϩ , and CD8 ϩ T-cell proliferation were evaluated by fluorescence-activated cell sorting (FACS) analysis. To examine the antigen-specific response, B cells isolated from Mycobacterium tuberculosis purified protein derivative (PPD) responder donors or tetanus toxoid (TT) responder donors were stimulated with CpG, IL-2, and PPD (Statens Serum Institute, Copenhagen, Denmark) or with TT (Novartis, Siena, Italy) at day zero. Toxins, CT-B, LTK63, and FSK were added on the same day. PPD and TT were also added on day 2. On day 3, cells were extensively washed, irradiated, and cocultured with autologous PBMC previously labeled with CFSE. CD4 ϩ and CD8 ϩ T-cell proliferation was evaluated after 5 days of coculture using a FACSCalibur and CellQuest software.
In some experiments anti-human CD86 and/or anti-human HLA-DR MAbs were used in order to block the interaction between APC and T cells in a mixed leukocyte reaction (MLR) assay. Briefly, B cells were incubated for 2 h at 4°C with 20 g/ml of anti-CD86 (BU63; mouse IgG1; Ancell Immunology Research Products, Bayport, MN) and/or anti-HLA-DR (G46-6; mouse IgG2a; BD Biosciences, San Diego, CA) MAbs, extensively washed to remove free MAbs, and then added to CFSE-labeled PBMC.
Cytokine production. Cytokine concentrations in supernatants collected from stimulated B cells treated as indicated above or left untreated for 3 days were determined by enzyme-linked immunosorbent assays (ELISA), including assays for tumor necrosis factor alpha (TNF-␣) and IL-1␤ (Pierce Endogen, Rockford, IL), IL-6 (BD Biosciences, San Diego, CA), and IL-12 (R&D Systems, Minneapolis, MN).
Statistical analysis. Microsoft Excel (Microsoft Corporation, Redmond, WA) was used for statistical analysis. Data were expressed as means Ϯ standard deviations, and statistical significance was determined by Student's t test. A P value of Ͻ0.05 was considered statistically significant.
RESULTS
CT and LT induce upregulation of surface activation markers. The levels of expression of activation markers CD86, CD80, HLA class I and II molecules, and CD40 on the B-cell surface were examined after treatment with CT, CT-B, LT, LTK63, FSK, or cAMP analogues, such as Db-cAMP and 8Br-cAMP, for 3 and 5 days. As shown in dot plots in Fig. 1 , isolated B cells cultured without polyclonal stimulation showed high mortality. For this reason we decided to perform the next experiments in the presence of polyclonal stimuli, which were also necessary for analysis of B-cell proliferation and cytokine production. CT and LT induce an increase in the intracellular cAMP levels. In order to check the enzymatic activity of adjuvants, intracellular cAMP was evaluated in B cells treated with the different compounds. As expected, CT, LT, and FSK, but not CT-B or LTK63, induced increases in intracellular cAMP levels in B cells (Fig. 2) . The results showed that there was a statistically significant difference (P Ͻ 0.05) between B cells treated with CT, LT, or FSK and untreated control (5,436 Ϯ 1,001, 5,054 Ϯ 1,142, 11,613 Ϯ 2,178, and 1,458 Ϯ 266 fmol/10 6 cells, respectively). Moreover, FSK-treated B cells contained statistically significant larger amounts of intracellular cAMP than toxin-treated cells (Fig. 2) .
CT and LT inhibit proliferation of B cells and increase their susceptibility to death. In order to evaluate the effect of adjuvants on cell proliferation, B lymphocytes were stained with CSFE and cultured for 3 and 5 days with polyclonal stimuli and with CT, CT-B, LT, LTK63, FSK, or cAMP analogues or left untreated. Figure 3 shows the results of a representative experiment. Polyclonal stimuli induced proliferation after 3 days of culture (67.7% proliferating B cells), which increased after 5 days (83.1%). Similar percentages of dividing B cells were evident when the cells were treated with CT-B or LTK63 (65.8% and 63.6%, respectively, at 3 days and 81.7% and 86.2%, respectively, at 5 days), suggesting that these compounds did not act on the ability of stimulated B cells to proliferate. Conversely, proliferation of CT-treated B cells, and to a lesser extent LT-treated B cells, was significantly less (P Ͻ 0.05) both at day 3 (35.3% and 45.5%, respectively) and at day 5 (62.9% and 71.7%, respectively). Similar results were obtained when B cells were treated with Db-cAMP and 8Br-cAMP (37.1% and 37.5%, respectively, at day 3 and 57.7% and 57.1%, respectively, at day 5). The inhibition of cell proliferation induced by toxins was evident not only based on the percentage of proliferating cells but also based on MFI, which indirectly indicated the rounds of B-cell division under each condition analyzed (Fig. 3) . When stimulated B cells were treated with FSK, their ability to proliferate was inhibited even more than it was when they were treated with toxins (18.7% at day 3 and 25.3% at day 5), probably because of the high dose of FSK used (50 M). The selection of this dose was based on the observation that lower doses were not sufficient to induce activation of human DC (5) .
At the same time, in order to understand if the evident inhibition of proliferation observed was related to an increase in B-cell death, the effects of toxins on B-cell viability were evaluated. The percentage of live cells was initially assessed by gating the events (R1) on a dot plot with forward and side scatter parameters (Fig. 4A) . On day 3, even if treatment with toxins, FSK, and cAMP analogues resulted in a slight reduction in viability, the viability of B cells was high under all conditions tested, suggesting that at this time cell death was not the cause of the marked inhibition of B-cell proliferation described above. After 5 days of culture the percentage of live B cells decreased to the same level in the control (untreated) or CT-B-or LTK63-treated samples. Treatment with FSK resulted in a further decrease in viability (P Ͻ 0.05), whereas CT, LT, and cAMP analogues induced a remarkable reduction in viability (P Ͻ 0.05). To confirm these results, we labeled the cells with Annexin V and PI after 3 and 5 days of culture in the presence or absence of adjuvants or FSK. As shown by the results of a representative experiment ( To analyze the antigen-specific T-cell activation induced by B-cell antigen presentation, toxin-treated B cells were used as APC in the autologous system in order to expand the antigenspecific T cells of either PPD or TT responder donors. The isolated B cells were stimulated with CpG, IL-2, and PPD protein or TT, and CT, LT, CT-B, LTK63, or FSK was added on the same day. After 3 days, cells were cocultured with autologous PBMC previously labeled with CFSE. The proliferation of PBMC, CD4
ϩ , and CD8 ϩ T cells was evaluated after 5 days of coculture by FACS analysis. As shown in Fig. 6 , only treatment with CT, LT, or FSK increased proliferation of autologous PBMC, CD4
ϩ , and CD8 ϩ T cells at any ratio of B cells to PBMC used, whereas CT-B or LTK63 did not enhance the antigen-presenting capacity of B lymphocytes.
In order to check the role of CD86 and HLA-DR in the improvement of the APC function of toxin-treated B cells, MLR experiments were performed in the presence of blocking MAb anti-CD86 and/or MAb anti-HLA-DR. As expected, the presence of both blocking reagents inhibited up to 80% of PBMC proliferation (Table 1) at ratio of B cells to PBMC of 1:4, indicating the evident contribution of these molecules in this system.
CT and LT inhibit TNF-␣ production while increasing IL-12, IL-1␤, and IL-6 production. To examine the effect of adjuvants on the production of cytokines, supernatants from B cells cultured for 3 days with polyclonal stimuli and treated with toxins, FSK, or nontoxic counterparts or left untreated were analyzed by ELISA. Figure 7 did not significantly influence the cytokine levels (228 and 237 pg/10 6 cells). As shown in Fig. 7 , toxin-and FSK-treated B cells showed significant production of IL-12 and IL-1␤ cytokines. In particular, high levels of IL-1␤ were detected in toxin-and FSK-treated samples (1,520, 1,211, and 1,781 pg/10 6 B cells treated with CT, LT, and FSK, respectively), whereas low but detectable concentrations of IL-12 were present in B-cell supernatants from CT-, LT-, and FSK-treated samples (260, 243, and 250 pg/10 6 B cells). Finally, treatment with toxins and FSK induced production of amounts of IL-6 larger than that in untreated B cells (1,947, 1,542, and 1,273 pg/10 6 cells for B cells treated with CT, LT, and FSK, respectively, versus 970 pg/10 6 cells for untreated B cells). However, the increase in IL-6 production was not statistically significant, probably due to the high variability among donors. Treatment with CT-B or LTK63 did not result in any significant difference in IL-12, IL-1␤, or IL-6 production compared to untreated samples.
Effect of adjuvants on sorted CD27
؉ and CD27 ؊ B-cell subpopulations. Finally, in order to determine if the different subsets of B cells were targeted differently by adjuvants, CD27 ϩ and CD27 Ϫ B cells were isolated and treated as described above for unsorted B cells. In particular, CD86 expression and susceptibility to death were analyzed for the two different B-cell populations after 3 days of culture. As shown in Fig. 8A , for both subsets a dramatic increase in the level of CD86 was evident in toxin-or FSK-treated cells compared to the corresponding untreated sample, while the presence of CT-B or LTK63 did not affect CD86 expression. Likewise, for induction of cell death, the results indicated that treatment with toxins had similar effects on the two subsets (Fig. 8B) . Indeed, at 3 days there was not a statistically significant difference in the percentages of Annexin V-and PI-labeled cells between the two subpopulations.
DISCUSSION
The specificity, magnitude, and quality of T-cell-mediated immune responses become conditioned during the early phase of antigen presentation. For this reason, analysis of the effects of adjuvants on APC could help identify the mechanism of action. In the population of APC that includes DC, B cells, and macrophages, DC are the most potent, and for this reason the majority of adjuvant studies are focused on these cells. We and other authors have previously shown that CT and LT were able to mature human DC and inhibit IL-12 and TNF-␣ production, whereas CT-B and LTK63 (5, 14, 15) did not have these abilities. Several papers described the APC function of B cells, indicating that in vivo B cells provide extra and essential antigen presentation capacity above that provided by DC, optimizing expansion and allowing generation of memory and effector T cells (9, 10, 17, 18, 23) . Therefore, we decided to investigate Our results show that the enzymatic activity of toxins is crucial for in vitro activation of human B cells and improvement of their APC capacity. Indeed, CT and LT, which increase intracellular cAMP levels, induced an evident activation state of human B cells, as judged by changes in surface phenotype, whereas none of the enzymatically inactive derivatives of CT or LT tested in this study were able to modify activation markers. In addition, the functional changes in B cells, including inhibition of proliferation, susceptibility to cell death, cytokine production, and an increase in the antigen-presenting capability induced by CT or LT, can be mimicked consistently by using the pharmacological agonist FSK or cAMP analogues.
To avoid the high rate of mortality of unstimulated B cells and to prolong the in vitro cultures, we decided to perform experiments in the presence of polyclonal stimuli. These stimuli, including antibody to human Ig as an antigen surrogate, CpG as a Toll-like receptor agonist, and IL-2 as a growth factor, are required for activation of both naïve and memory B cells in the absence of CD4 ϩ T cells (7). Treatment with toxins was able to increase the expression of CD86 and HLA class II, confirming results obtained by other workers (2) . Conversely, CT-B and LTK63, even if they were used at concentrations higher than those used for the toxins, were unable to upregulate the activation markers on human B cells. Recently, Schnit- zler et al. showed that treatment of murine B cells with CT-B induced a sequence of signaling events related to cellular activation and surface molecule expression (37) . In our study, treatment of both unstimulated and polyclonal activated human B cells with CT-B did not induce any variations in surface activation markers and antigen presentation, suggesting that there is a difference in behavior between human and murine B cells. The precise mechanism of action of these adjuvants has not been completely elucidated, and there are controversies concerning the requirements for and roles of the A and B subunits of these toxins both in vitro and in vivo (reviewed in reference 16). Factors involved in the dissimilar findings include the route of administration, the characteristics of the vaccine antigen, contamination of the adjuvant with endotoxin or with holotoxin, and the species of animal used. The difference between the human and murine cell responses to nontoxic derivatives of toxins could be another important factor that should be taken into account in the design and development of mucosal adjuvants suitable for human vaccination.
It is known that the second messenger cAMP can have immunosuppressive effects on T and B lymphocytes (28, 32, 38) . We confirmed these findings, showing that CT, LT, FSK, and cAMP analogues inhibited the proliferation of B cells induced by polyclonal stimuli. FSK-treated B cells produced larger amounts of intracellular cAMP than toxin-treated cells, suggesting that the difference could represent a possible reason for the more pronounced inhibition of proliferation seen for FSK-treated cells. These results are in agreement with those obtained previously by our group (39) and by Johnson et al. (21) , showing that increased levels of cAMP were able to inhibit in a dose-dependent manner anti-CD3-or IL-2-induced T-cell proliferation. In addition, toxins and FSK made B cells more susceptible to death. Conversely, treatment with CT-B or LTK63, which lack enzymatic activity, did not alter either the ability of stimulated B cells to proliferate or the induction of cell death. These results were expected, since it has been shown that cAMP is involved in the regulation of apoptosis in B progenitor and mature B cells by inducing activation of protein kinase A (25, 29) , suggesting that physiological ligands that control cellular cAMP levels could play an important role in the regulation of B-cell maturation in vivo. Indeed, compounds acting on the increase in intracellular cAMP content could have pleiotropic effects on the immune cells, inducing both suppressive (inhibition of proliferation) and stimulatory signals (activation) at the same time. The final effect observed in vitro and even more in vivo upon treatment with toxins is probably due to a balance of these signals.
In order to determine if the effects of toxins were directed mostly toward a particular subset of B cells, such as CD27 ϩ or CD27 Ϫ populations, we first evaluated the expression of GM1 on gated CD27 ϩ and CD27 Ϫ B cells by using FITC-labeled CT-B. The results indicated that there was a slightly higher level of binding to CD27 Ϫ B cells (data not shown). However, when CD86 expression and induction of cell death after treatment with toxins were evaluated for the two different B-cell populations, the results indicated that CT and LT acted similarly in both subsets. Taken together, our data indicated that the toxins induced a real increase in CD86 expression in total B cells and did not cause selective depletion of the population with a low level of CD86 expression.
Finally, to investigate the effects of the adjuvants on the antigen-presenting function of human B cells, both allo-MLR and antigen-specific T-cell proliferation tests were performed. The ability of B cells treated with CT, LT, or FSK to induce T-cell proliferation was evident in both the assays. The data could be explained by the fact that toxins and FSK were able to induce an activation state with upregulation of costimulatory molecules and HLA class II, which was responsible for the increased antigen-presenting function observed. Indeed, as expected, the use of blocking MAbs against CD86 and/or HLA-DR in the MLR assay resulted in a high level of inhibition of PBMC proliferation. Again, treatment with CT-B and LTK63 did not improve the APC capacity of stimulated B cells, further confirming the role of cAMP in the adjuvant activity of toxins. We and other authors reported that CT and LT inhibit IL-12 and TNF-␣ production by human DC, partially explaining the polarization of CD4 ϩ T cells toward a Th2 phenotype observed when CT-or LT-treated DC were used as APC (5, 14, 15) . In this study, we detected strong inhibition of TNF-␣ production upon treatment of B cells with CT, LT, or FSK, further supporting the role of cAMP in the modulation of B-cell functions. Surprisingly, in contrast to the results for DC treated with CT or LT, we observed IL-12 production in toxintreated B cells and strong production of IL-1␤. As reported in other papers (reviewed in reference 16), we confirmed that CT and LT induced an increase in IL-6 production. This peculiar pattern of cytokines induced by treatment with toxins could be important for the generation of an environment able to drive the Th1/Th2 polarization of T cells. Additional studies are required to investigate this issue.
In this work, several observations support the hypothesis that CT and LT directly activate human B cells predominantly by elevating the intracellular cAMP level. We cannot exclude the possibility that there is concomitant involvement of other factors, including the signaling induced by binding with their receptors. Although in our model system the presence of enzymatic activity is required for the adjuvanticity of toxins, suggesting that LTK63 and CT-B do not act directly on these APC, we cannot rule out the possibility that there is an indirect effect on APC that is induced by these compounds in vivo. Our results are in agreement with the results of other studies based on a requirement for the A subunit of CT for the induction of adjuvanticity of B cells. Indeed, it has been demonstrated that CTA1-DD, an adjuvant based on the CT A subunit genetically linked to two Ig-binding domains (DD) of staphylococcal protein A, but not enzymatically inactive mutants, was able to target and activate B cells and act as a good mucosal adjuvant in vivo (1, 12) . In this study, our objective was to determine if the enzymatic activity is mandatory for the APC function of B cells, and therefore we focused on reagents with 0% or 100% activity. It would be interesting to check the minimum level of enzymatic activity required for adjuvanticity with human B cells by using recombinant enterotoxins with greatly reduced enzymatic activity.
Together with our previous data (14, 15) , results obtained in this study allow us to conclude that the adjuvanticity of toxins, measured as in vitro activation and the antigen-presenting ability of human APC (both DC and B cells), is stringently correlated to the presence of the enzymatic activity involved in the increase in the intracellular cAMP content.
